2.24 USD
+0.00
0.00%
At close Jan 21, 4:00 PM EST
Pre-market
2.25
+0.01
0.45%
1 day
0.00%
5 days
-1.32%
1 month
19.79%
3 months
21.08%
6 months
14.87%
Year to date
14.87%
1 year
-23.81%
5 years
-38.80%
10 years
-66.57%
 

About: Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Employees: 987

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

100% more call options, than puts

Call options by funds: $48K | Put options by funds: $24K

12% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 33

10% more funds holding

Funds holding: 115 [Q2] → 126 (+11) [Q3]

4% less capital invested

Capital invested by funds: $104M [Q2] → $99.3M (-$4.34M) [Q3]

2.23% less ownership

Funds ownership: 57.4% [Q2] → 55.17% (-2.23%) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for ARAY.

Financial journalist opinion

Based on 8 articles about ARAY published over the past 30 days

Neutral
PRNewsWire
23 hours ago
Leonel Peralta to Join Accuray as Chief Operations Officer
MADISON, Wis. , Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025.
Leonel Peralta to Join Accuray as Chief Operations Officer
Positive
Zacks Investment Research
1 day ago
Accuray (ARAY) Shows Fast-paced Momentum But Is Still a Bargain Stock
Accuray (ARAY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Accuray (ARAY) Shows Fast-paced Momentum But Is Still a Bargain Stock
Positive
Zacks Investment Research
1 week ago
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions
Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions
Neutral
PRNewsWire
1 week ago
Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
MADISON, Wis. , Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Administration (NMPA).
Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
Positive
Zacks Investment Research
1 week ago
Here's Why You Should Add Accuray Stock to Your Portfolio Now
ARAY's solid product demand and revenue growth raise optimism about the stock.
Here's Why You Should Add Accuray Stock to Your Portfolio Now
Positive
Seeking Alpha
2 weeks ago
Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'
Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue.
Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'
Positive
Zacks Investment Research
2 weeks ago
Here Is Why Bargain Hunters Would Love Fast-paced Mover Accuray (ARAY)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Accuray (ARAY)
Positive
Zacks Investment Research
3 weeks ago
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
Positive
Zacks Investment Research
1 month ago
ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM
Accuray announces positive study data for its CyberKnife System in treating brainstem metastases.
ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM
Neutral
PRNewsWire
1 month ago
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat
Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications MADISON, Wis., Dec. 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an international retrospective multicenter analysis found that radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT), delivered with the CyberKnife® System, can provide an effective and time-saving treatment option for brainstem metastases (BSM).
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat
Charts implemented using Lightweight Charts™